As of 29 June 2018, the last trading day of the month, the aggregate number of shares and votes in Karo Pharma AB amounts to 164,332,782. The increase in the number of shares and votes is attributable to the recently completed rights issue of 54,777,594 shares. The rights issue was announced on 4 April 2018.
FOR FURTHER INFORMATION PLEASE CONTACT:
Peter Blom, CEO, +46 (0) 70-655 56 98 or email@example.com
ABOUT KARO PHARMA
Karo Pharma is a Specialty Pharmaceutical company, which develops and markets products for pharmacies as well as directly to healthcare sector. Karo Pharma is listed on Nasdaq Stockholm Mid Cap.
This information is information that Karo Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the above contact person’s agency, at 08:00 CEST on 29 June 2018.